A systematic review of the therapeutic interventions for heterotopic ossification after spinal cord injury

Spinal Cord

Volumn 48, Issue 7, 2010, Pages 512-521

  Teasell, R W ^a,b   Mehta, S ^b   Aubut, J L ^b   Ashe, M C ^c,d   Sequeira, K ^a   MacAluso, S ^a   Tu, L ^b  

^a WESTERN UNIVERSITY   (Canada)

^b LAWSON HEALTH RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d CENTRE FOR HIP HEALTH AND MOBILITY   (Canada)

Author keywords

HO; spinal cord injury; therapeutic interventions

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ETIDRONIC ACID; INDOMETACIN; NONSTEROID ANTIINFLAMMATORY AGENT; PAMIDRONIC ACID; PLACEBO; ROFECOXIB; WARFARIN;

ABDOMINAL DISCOMFORT; CLINICAL ASSESSMENT; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFICACY; ELECTROMAGNETIC FIELD; EXCISION REPAIR; GASTROINTESTINAL SYMPTOM; HETEROTOPIC OSSIFICATION; HUMAN; INTERVENTION STUDY; IRRADIATION; MEDICAL RESEARCH; PRIORITY JOURNAL; PROPHYLAXIS; PULSE LOW INTENSITY ELECTROMAGNETIC FIELD; RADIATION DOSE; REVIEW; SPINAL CORD INJURY; SYSTEMATIC REVIEW; BIBLIOGRAPHIC DATABASE; COMPLICATION; OSSIFICATION, HETEROTOPIC; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPINAL CORD INJURIES; STATISTICS AND NUMERICAL DATA;

DATABASES, BIBLIOGRAPHIC; HUMANS; OSSIFICATION, HETEROTOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPINAL CORD INJURIES;

EID: 77954313788     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2009.175     Document Type: Review

References (42)

1. Buschbacher R, McKinley W, Buschbacher L, Devaney CW, Coplin B. Warfarin in prevention of heterotopic ossification. Am J Phys Med Rehabil 1992; 71: 86-91.
2. van Kuijk AA, Geurts AC, van Kuppevelt HJ. Neurogenic heterotopic ossification in spinal cord injury. Spinal Cord 2002; 40: 313-326.
3. Banovac K, Williams JM, Patrick LD, Haniff YM. Prevention of heterotopic ossification after spinal cord injury with indometha-cin. Spinal Cord 2001; 39: 370-374.
4. Orzel JA, Rudd TG. Heterotopic bone formation: clinical, laboratory, and imaging correlation. J Nucl Med 1985; 26: 125-132.
5. Freed JH, Hahn H, Menter R, Dillon T. The use of the three-phase bone scan in the early diagnosis of heterotopic ossification (HO) and in the evaluation of Didronel therapy. Paraplegia 1982; 20: 208-216.
6. Amendola MA, Shirazi K, Amendola BE, Kuhns LR, Tisnado J, Yaghmai I. Computed tomography of malignant tumors of the osseous pelvis. Comput Radiol 1983; 7: 107-117.
7. Thomas EA, Cassar-Pullicino VN, McCall IW. The role of ultrasound in the early diagnosis and management of heterotopic bone formation. Clin Radiol 1991; 43: 190-196.
8. Singh RS, Craig MC, Katholi CR, Jackson AB, Mountz JM. The predictive value of creatine phosphokinase and alkaline phosphatase in identification of heterotopic ossification in patients after spinal cord injury. Arch Phys Med Rehabil 2003; 84: 1584-1588.
9. Tibone J, Sakimura I, Nickel VL, Hsu JD. Heterotopic ossification around the hip in spinal cord-injured patients. A long-term follow-up study. J Bone Joint Surg Am 1978; 60: 769-775.
10. Welch K, Goldberg D. Serum creatine phosphokinase in motor neuron disease. Neurology 1973; 22: 697-701.
11. Rossier AB, Bussat P, Infante F, Zender R, Courvoisier B, Muhelm G et al. Current facts of para-osteo-arthropathy (POA). Paraplegia 1973; 11: 38-78.
12. Schurch B, Capaul M, Vallotton MB, Rossier AB. Prostaglandin E2 measurements: their value in the early diagnosis of heterotopic ossification in spinal cord injury patients. Arch Phys Med Rehabil 1997; 78: 687-691.
13. Lal S, Hamilton BB, Heinemann A, Betts HB. Risk factors for heterotopic ossification in spinal cord injury. Arch Phys Med Rehabil 1989; 70: 387-390.
14. Bravo-Payno P, Esclarin A, Arzoz T, Arroyo O, Labarta C. Incidence and risk factors in the appearance of heterotopic ossification in spinal cord injury. Paraplegia 1992; 30: 740-745.
15. Wittenberg RH, Peschke U, Botel U. Heterotopic ossification after spinal cord injury. Epidemiology and risk factors. J Bone Joint Surg Br 1992; 74: 215-218.
16. Colachis III SC, Clinchot DM. The association between deep venous thrombosis and heterotopic ossification in patients with acute traumatic spinal cord injury. Paraplegia 1993; 31: 507-512.
17. Eng JJ, Teasell RW, Miller WC, Wolfe DL, Townson AF, Hsieh JTC et al. (eds). Spinal Cord Injury Rehabilitation Evidence, 2nd edn. Lulu: Vancouver, 2008. Available at www.icord.org/scire.
18. Eng JJ, Teasell RW, Miller WC, Wolfe DL, Townson AF, Aubut JL et al. Spinal Cord Injury Rehabilitation Evidence: methods of the SCIRE systematic review. Top Spinal Cord Inj Rehabil 2007; 13: 1-10.
19. Moseley AM, Herbert RD, Sherrington C, Maher CG. Evidence for physiotherapy practice: a survey of the Physiotherapy Evidence Database (PEDro). Aust J Physiother 2002; 48: 43-49.
20. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 1998; 52: 377-384.
21. Straus SE, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM, Third Edition ed Elsevier Churchill Livingstone: Toronto, 2005.
22. Banovac K, Williams JM, Patrick LD, Levi A. Prevention of heterotopic ossification after spinal cord injury with COX-2 selective inhibitor (rofecoxib). Spinal Cord 2004; 42: 707-710.
23. Durovic A, Miljkovic D, Brdareski Z, Plavsic A, Jevtic M. Pulse low-intensity electromagnetic field as prophylaxis of heterotopic ossification in patients with traumatic spinal cord injury. Vojnosanit Pregl 2009; 66: 22-28.
24. Banovac K, Gonzalez F, Renfree KJ. Treatment of heterotopic ossification after spinal cord injury. J Spinal Cord Med 1997; 20: 60-65.
25. Banovac K, Gonzalez F, Wade N, Bowker JJ. Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification. Paraplegia 1993; 31: 660-666.
26. Banovac K. The effect of etidronate on late development of heterotopic ossification after spinal cord injury. J Spinal Cord Med 2000; 23: 40-44.
27. Garland DE, Alday B, Venos KG, Vogt JC. Diphosphonate treatment for heterotopic ossification in spinal cord injury patients. Clin Orthop Relat Res 1983; 176: 197-200.
28. Subbarao JV, Nemchausky BA, Gratzer M. Resection of hetero-topic ossification and Didronel therapyFregaining wheelchair independence in the spinal cord injured patient. J Am Paraplegia Soc 1987; 10: 3-7.
29. Schuetz P, Mueller B, Christ-Crain M, Dick W, Haas H. Amino-bisphosphonates in heterotopic ossification: first experience in five consecutive cases. Spinal Cord 2005; 43: 604-610.
30. Chao CY, Cheing GL. The effects of lower-extremity functional electric stimulation on the orthostatic responses of people with tetraplegia. Arch Phys Med Rehabil 2005; 86: 1427-1433.
31. Chao ST, Joyce MJ, Suh JH. Treatment of heterotopic ossification. Orthopedics 2007; 30: 457-464.
32. Sautter-Bihl ML, Hultenschmidt B, Liebermeister E, Nanassy A. Fractionated and single-dose radiotherapy for heterotopic bone formation in patients with spinal cord injury. A phase-I/II study. Strahlenther Onkol 2001; 177: 200-205.
33. Sautter-Bihl ML, Liebermeister E, Nanassy A. Radiotherapy as a local treatment option for heterotopic ossifications in patients with spinal cord injury. Spinal Cord 2000; 38: 33-36.
34. Meiners T, Abel R, Bohm V, Gerner HJ. Resection of heterotopic ossification of the hip in spinal cord injured patients. Spinal Cord 1997; 35: 443-445.
35. Garland DE, Orwin JF. Resection of heterotopic ossification in patients with spinal cord injuries. Clin Orthop Relat Res 1989; 242: 169-176.
36. Macfarlane RJ, Ng BH, Gamie Z, El Masry MA, Velonis S, Schizas C et al. Pharmacological treatment of heterotopic ossification following hip and acetabular surgery. Expert Opin Pharmacother 2008; 9: 767-786.
37. Buring K. On the origin of cells in heterotopic bone formation. Clin Orthop Relat Res 1975; 110: 293-301.
38. Jensen LL, Halar E, Little JW, Brooke MM. Neurogenic heterotopic ossification. Am J Phys Med 1987; 66: 351-363.
39. Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol 2008; 102: 10-14.
40. Shehab D, Elgazzar AH, Collier BD. Heterotopic ossification. J Nucl Med 2002; 43: 346-353.
41. Anthony P, Keys H, Evarts CM, Rubin P, Lush C. Prevention of heterotopic bone formation with early post operative irradiation in high risk patients undergoing total hip arthroplasty: comparison of 10.00 Gy vs 20.00 Gy schedules. Int J Radiat Oncol Biol Phys 1987; 13: 365-369.
42. Stover SL, Niemann KM, Miller III JM. Disodium etidronate in the prevention of postoperative recurrence of heterotopic ossification in spinal-cord injury patients. J Bone Joint Surg Am 1976; 58: 683-688.